InterPAD - DETAILS

Linagliptin, 668270-12-0, Tradjenta, Ondero, BI-1356, BI 1356, Trajenta, Trazenta, Linagliptin (BI-1356), BI-1356-BS, BS 1356 BS, UNII-3X29ZEJ4R2, 3X29ZEJ4R2, CHEBI:68610, BI-1356BS, HSDB 8204, BI 1356 BS, BS-1356-BS, (R)-8-(3-Amino-piperidin-1-yl)-7-but-2-ynyl-3-methyl-1-(4-methyl-quinazolin-2-ylmethyl)-3,7-dihydro-purine-2,6-dione, ione, CHEMBL237500, GLYXAMBI COMPONENT LINAGLIPTIN, (R)-8-(3-aminopiperidin-1-yl)-7-but-2-ynyl-3-methyl-1-(4-methylquinazolin-2-ylmethyl)-3,7-dihydro-purine-2,6-dione, TRIJARDY XR COMPONENT LINAGLIPTIN, LINAGLIPTIN (MART.), LINAGLIPTIN [MART.], (R)-8-(3-aminopiperidin-1-yl)-7-(but-2-ynyl)-3-methyl-1-((4-methylquinazolin-2-yl)methyl)-1H-purine-2,6(3H,7H)-dione, 1H-Purine-2,6-dione, 8-((3R)-3-amino-1-piperidinyl)-7-(2-butynyl)-3,7-dihydro-3-methyl-1-((4-methyl-2-quinazolinyl)methyl)-, 8-[(3R)-3-aminopiperidin-1-yl]-7-(but-2-yn-1-yl)-3-methyl-1-[(4-methylquinazolin-2-yl)methyl]-3,7-dihydro-1H-purine-2,6-dione, 8-[(3r)-3-Aminopiperidin-1-Yl]-7-But-2-Yn-1-Yl-3-Methyl-1-[(4-Methylquinazolin-2-Yl)methyl]-3,7-Dihydro-1h-Purine-2,6-Dione, (R)-8-(3-Aminopiperidin-1-yl)-7-(but-2-yn-1-yl)-3-methyl-1-((4-methylquinazolin-2-yl)methyl)-1H-purine-2,6(3H,7H)-dione, 8-[(3R)-3-aminopiperidin-1-yl]-7-(but-2-yn-1-yl)-3- methyl-1-[(4-methylquinazolin-2-yl)methyl]-3,7-dihydro-1H-purine-2,6-dione, 8-[(3R)-3-aminopiperidin-1-yl]-7-but-2-ynyl-3-methyl-1-[(4-methylquinazolin-2-yl)methyl]purine-2,6-dione, linagliptine, linagliptinum, Linagliptina, Linaglitpin, Linagliptin [USAN:INN:JAN], Tradjenta (TN), 8-((3R)-3-AMINOPIPERIDIN-1-YL)-7-(BUT-2-YN-1-YL)-3-METHYL-1-((4-METHYLQUINAZOLIN-2-YL)METHYL)-3,7-DIHYDRO-1H-PURINE-2,6-DIONE, BI1356, 8-[(3R)-3-Amino-1-piperidinyl]-7-(2-butynyl)-3,7-dihydro-3-methyl-1-[(4-methyl-2-quinazolinyl)methyl]-1H-purine-2,6-dione, LINAGLIPTIN [MI], LINAGLIPTIN [INN], LINAGLIPTIN [JAN], LINAGLIPTIN [USAN], LINAGLIPTIN [VANDF], LINAGLIPTIN [WHO-DD], Linagliptin (BI-1356)?, MLS006010217, SCHEMBL160188, Linagliptin (JAN/USAN/INN), GTPL6318, A10BH05, AMY8953, EX-A076, LINAGLIPTIN [ORANGE BOOK], LTXREWYXXSTFRX-QGZVFWFLSA-N, BCPP000185, DTXSID201021653, GLXC-10521, BCP02462, BDBM50228403, MFCD14635356, s3031, AKOS015951179, AKOS015995251, AC-8761, BCP9000854, CCG-269463, CS-0637, DB08882, LINAGLIPTIN COMPONENT OF GLYXAMBI, NCGC00346655-01, NCGC00346655-02, NCGC00346655-08, AS-35080, BL164627, HY-10284, JENTADUETO COMPONENT OF LINAGLIPTIN, LINAGLIPTIN COMPONENT OF JENTADUETO, SMR004701306, LINAGLIPTIN COMPONENT OF TRIJARDY XR, FT-0670793, NS00098773, SW219813-1, D09566, AB01563307_01, AB01563307_03, EN300-6481354, Q909745, J-519354, Z2235801970, (R)-8-(3-aminopiperidin-1-yl)-7-(but-2-yn-1-yl)-3-methyl-1-((4-methylquinazolin-2-yl)methyl)-3,7-dihydro-1H-purine-2,6-dione, 1-[(4-methyl-quinazolin-2-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-(3-(R)-aminopiperidin-1-yl)xanthine, 1-[(4-methyl-quinazolin-2-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-(3-(R)aminopiperidin-1-yl)xanthine, 1-[(4-methyl-quinazolin-2yl) methyl]-3-methyl-7-(2-butyn-1-yl)-8-[3-(R) amino-piperidin-1-yl]-xanthine, 1-[(4-Methylquinazolin-2-yl)-methyl]-3-methyl-7-(2-butin-1-yl)-8-(3-(R)-aminopiperidin-1-yl)-xanthine, 1-[(4-Methylquinazolin-2-yl)methyl]-3-methyl-7-(2-butin-1-yl)-8-(3-(R)-aminopiperidin-1-yl)-xanthine, 1233245-11-8, 1H-PURINE-2,6-DIONE, 8-((3R)-3-AMINO-1-PIPERIDINYL)-7-(2-BUTYNYL)-3,7-DIHYDRO-3-METHYL-1-((4-METHYL-2- QUINAZOLINYL)METHYL)-, 8-[(3R)-3-aminopiperidin-1-yl]-7-(but-2-yn-1-yl)-3-methyl-1-[(4-methylquinazolin-2-yl)methyl]-2,3,6,7-tetrahydro-1H-purine-2,6-dione, 8-[(3R)-3-Aminopiperidin-1-yl]-7-but-2-yn-1-yl-3-methyl-1-[(4-methylquinazolin-2-yl)methyl]-3,7-dihydro-1H-purine-2,6-d, 8-[(3R)-3-Aminopiperidin-1-yl]-7-but-2-yn-1-yl-3-methyl-1-[(4-methylquinazolin-2-yl)methyl]-3,7-dihydro-1H-purine-2,6-d ione

Name	Linagliptin
PubChem CID	10096344
Molecular Weight	472.5g/mol
Synonyms	Linagliptin, 668270-12-0, Tradjenta, Ondero, BI-1356, BI 1356, Trajenta, Trazenta, Linagliptin (BI-1356), BI-1356-BS, BS 1356 BS, UNII-3X29ZEJ4R2, 3X29ZEJ4R2, CHEBI:68610, BI-1356BS, HSDB 8204, BI 1356 BS, BS-1356-BS, (R)-8-(3-Amino-piperidin-1-yl)-7-but-2-ynyl-3-methyl-1-(4-methyl-quinazolin-2-ylmethyl)-3,7-dihydro-purine-2,6-dione, ione, CHEMBL237500, GLYXAMBI COMPONENT LINAGLIPTIN, (R)-8-(3-aminopiperidin-1-yl)-7-but-2-ynyl-3-methyl-1-(4-methylquinazolin-2-ylmethyl)-3,7-dihydro-purine-2,6-dione, TRIJARDY XR COMPONENT LINAGLIPTIN, LINAGLIPTIN (MART.), LINAGLIPTIN [MART.], (R)-8-(3-aminopiperidin-1-yl)-7-(but-2-ynyl)-3-methyl-1-((4-methylquinazolin-2-yl)methyl)-1H-purine-2,6(3H,7H)-dione, 1H-Purine-2,6-dione, 8-((3R)-3-amino-1-piperidinyl)-7-(2-butynyl)-3,7-dihydro-3-methyl-1-((4-methyl-2-quinazolinyl)methyl)-, 8-[(3R)-3-aminopiperidin-1-yl]-7-(but-2-yn-1-yl)-3-methyl-1-[(4-methylquinazolin-2-yl)methyl]-3,7-dihydro-1H-purine-2,6-dione, 8-[(3r)-3-Aminopiperidin-1-Yl]-7-But-2-Yn-1-Yl-3-Methyl-1-[(4-Methylquinazolin-2-Yl)methyl]-3,7-Dihydro-1h-Purine-2,6-Dione, (R)-8-(3-Aminopiperidin-1-yl)-7-(but-2-yn-1-yl)-3-methyl-1-((4-methylquinazolin-2-yl)methyl)-1H-purine-2,6(3H,7H)-dione, 8-[(3R)-3-aminopiperidin-1-yl]-7-(but-2-yn-1-yl)-3- methyl-1-[(4-methylquinazolin-2-yl)methyl]-3,7-dihydro-1H-purine-2,6-dione, 8-[(3R)-3-aminopiperidin-1-yl]-7-but-2-ynyl-3-methyl-1-[(4-methylquinazolin-2-yl)methyl]purine-2,6-dione, linagliptine, linagliptinum, Linagliptina, Linaglitpin, Linagliptin [USAN:INN:JAN], Tradjenta (TN), 8-((3R)-3-AMINOPIPERIDIN-1-YL)-7-(BUT-2-YN-1-YL)-3-METHYL-1-((4-METHYLQUINAZOLIN-2-YL)METHYL)-3,7-DIHYDRO-1H-PURINE-2,6-DIONE, BI1356, 8-[(3R)-3-Amino-1-piperidinyl]-7-(2-butynyl)-3,7-dihydro-3-methyl-1-[(4-methyl-2-quinazolinyl)methyl]-1H-purine-2,6-dione, LINAGLIPTIN [MI], LINAGLIPTIN [INN], LINAGLIPTIN [JAN], LINAGLIPTIN [USAN], LINAGLIPTIN [VANDF], LINAGLIPTIN [WHO-DD], Linagliptin (BI-1356)?, MLS006010217, SCHEMBL160188, Linagliptin (JAN/USAN/INN), GTPL6318, A10BH05, AMY8953, EX-A076, LINAGLIPTIN [ORANGE BOOK], LTXREWYXXSTFRX-QGZVFWFLSA-N, BCPP000185, DTXSID201021653, GLXC-10521, BCP02462, BDBM50228403, MFCD14635356, s3031, AKOS015951179, AKOS015995251, AC-8761, BCP9000854, CCG-269463, CS-0637, DB08882, LINAGLIPTIN COMPONENT OF GLYXAMBI, NCGC00346655-01, NCGC00346655-02, NCGC00346655-08, AS-35080, BL164627, HY-10284, JENTADUETO COMPONENT OF LINAGLIPTIN, LINAGLIPTIN COMPONENT OF JENTADUETO, SMR004701306, LINAGLIPTIN COMPONENT OF TRIJARDY XR, FT-0670793, NS00098773, SW219813-1, D09566, AB01563307_01, AB01563307_03, EN300-6481354, Q909745, J-519354, Z2235801970, (R)-8-(3-aminopiperidin-1-yl)-7-(but-2-yn-1-yl)-3-methyl-1-((4-methylquinazolin-2-yl)methyl)-3,7-dihydro-1H-purine-2,6-dione, 1-[(4-methyl-quinazolin-2-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-(3-(R)-aminopiperidin-1-yl)xanthine, 1-[(4-methyl-quinazolin-2-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-(3-(R)aminopiperidin-1-yl)xanthine, 1-[(4-methyl-quinazolin-2yl) methyl]-3-methyl-7-(2-butyn-1-yl)-8-[3-(R) amino-piperidin-1-yl]-xanthine, 1-[(4-Methylquinazolin-2-yl)-methyl]-3-methyl-7-(2-butin-1-yl)-8-(3-(R)-aminopiperidin-1-yl)-xanthine, 1-[(4-Methylquinazolin-2-yl)methyl]-3-methyl-7-(2-butin-1-yl)-8-(3-(R)-aminopiperidin-1-yl)-xanthine, 1233245-11-8, 1H-PURINE-2,6-DIONE, 8-((3R)-3-AMINO-1-PIPERIDINYL)-7-(2-BUTYNYL)-3,7-DIHYDRO-3-METHYL-1-((4-METHYL-2- QUINAZOLINYL)METHYL)-, 8-[(3R)-3-aminopiperidin-1-yl]-7-(but-2-yn-1-yl)-3-methyl-1-[(4-methylquinazolin-2-yl)methyl]-2,3,6,7-tetrahydro-1H-purine-2,6-dione, 8-[(3R)-3-Aminopiperidin-1-yl]-7-but-2-yn-1-yl-3-methyl-1-[(4-methylquinazolin-2-yl)methyl]-3,7-dihydro-1H-purine-2,6-d, 8-[(3R)-3-Aminopiperidin-1-yl]-7-but-2-yn-1-yl-3-methyl-1-[(4-methylquinazolin-2-yl)methyl]-3,7-dihydro-1H-purine-2,6-d ione
Drug Type	Small molecule
Formula	C₂₅H₂₈N₈O₂
SMILES	CC#CCN1C2=C(N=C1N3CCCC(C3)N)N(C(=O)N(C2=O)CC4=NC5=CC=CC=C5C(=N4)C)C
InChI	1S/C25H28N8O2/c1-4-5-13-32-21-22(29-24(32)31-12-8-9-17(26)14-31)30(3)25(35)33(23(21)34)15-20-27-16(2)18-10-6-7-11-19(18)28-20/h6-7,10-11,17H,8-9,12-15,26H2,1-3H3/t17-/m1/s1
InChIKey	LTXREWYXXSTFRX-QGZVFWFLSA-N
CAS Number	668270-12-0
ChEMBL ID	CHEMBL237500
ChEBI ID	CHEBI:68610
TTD ID	D02EYG
Drug Bank ID	DB08882
KEGG ID	D09566
Toxicity	Organism	Test Type	Route(Dose)
	rat	LD50	intraperitoneal(165 mg/kg)
	mouse	LD50	intraperitoneal(254 mg/kg)
	rat	LD50	oral(322 mg/kg)
Structure			Download 2D MOL 3D MOL

Pair Name	Niacinamide, Linagliptin
Partner Name	Niacinamide
Result	The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents. These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.